NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-23 16:42இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Solara Reports Best Quarter in 5 Years: Q2 FY27 PAT at ₹28.5 Cr; Revenue Up 33% to ₹418 Cr
Solara Active Pharma Sciences reported a strong turnaround for Q2 FY27, with revenue growing 33% YoY to ₹418 crore and PAT reaching ₹28.5 crore compared to a ₹10 crore loss in Q2 FY26. EBITDA more than doubled to ₹77 crore (up 118% YoY) with EBITDA margins expanding 720 bps to 18.4%. The company's core base business generated ₹327 crore (up 37% YoY), while the drag from its Ibuprofen portfolio narrowed significantly to near breakeven. Additionally, debt was reduced by ₹114 crore during H1 FY27, which helped trim net finance costs by 16% QoQ.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the Q2 FY27 earnings call transcript highlighting Solara's turnaround to strong profitability and ongoing deleveraging.
ஏன் இது முக்கியம்Demonstrates operational turnaround after years of net losses, driven by base business expansion to regulated markets (78% of revenue) and narrowing losses in the commodity Ibuprofen segment.
Q2 FY27 Revenue: ₹418 கோடிQ2 FY27 PAT: ₹28.5 கோடிQ2 FY27 EBITDA Margin: 18.4%H1 FY27 Debt Reduction: ₹114 கோடிDebt reduction vs Total Debt: ~21% of ₹542 Cr debt
📅 குறுகிய காலம்Sentiment is likely to remain supported by strong operating profitability and cash generation aiding balance sheet deleveraging.
📈 நீண்ட காலம்Structural recovery hinges on successfully concluding the strategic review of the Ibuprofen business, scaling higher-margin CRAMS/CDMO offerings, and sustaining DMF filings.
⚠ அபாய எச்சரிக்கைகள்
Pricing volatility and Chinese competition in commodity Ibuprofen
Supply chain and cost inflation risks driven by the West Asia crisis
Asset write-downs/losses (e.g., ₹4.5 crore exceptional loss on unutilized equipment at Vizag)
👀 கவனிக்க வேண்டியவை
Track the outcome of the strategic review of the Ibuprofen business due in ~12 weeks and monitor whether the >18% EBITDA margin is sustainable against raw material and West Asia supply disruptions.
Q2 FY27 PAT Swings to ₹28.5 Cr; EBITDA Doubles to ₹76.9 Cr, Best Quarter in 5 Years
Solara Active Pharma Sciences reported a strong turnaround in Q2 FY27 with revenue growing 33% YoY to ₹417.8 Cr (₹4,178 Mn) and EBITDA surging 118% YoY to ₹76.9 Cr (₹769 Mn). The company returned to profitability, reporting PAT of ₹28.5 Cr compared to a net loss of ₹10.1 Cr in Q2 FY26. Growth was propelled by the core Base API business (revenue up 37% YoY to ₹327.3 Cr) and narrowing EBITDA losses in the commodity Ibuprofen segment to ₹0.2 Cr. Net debt declined by 19% over H1 FY27 to ₹500 Cr, bringing Net Debt/EBITDA down to 1.8x from 3.2x in FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுSolara achieved its strongest quarterly operating profit in five years, driven by base API expansion, Ibuprofen business turning near-breakeven, and debt reduction.
ஏன் இது முக்கியம்Represents a significant operational turnaround from FY24-FY26 losses, strengthening balance sheet leverage and expanding base business margins above 23%.
📅 குறுகிய காலம்Earnings surprise and sharp expansion in operating margins to 18.4% should improve sentiment ahead of the Q2 earnings conference call.
📈 நீண்ட காலம்De-leveraging to 1.8x EBITDA and strategic pivoting toward high-margin complex APIs support structural margin improvement, contingent on the final decision regarding the Ibuprofen segment.
⚠ அபாய எச்சரிக்கைகள்
Inflationary pressure on raw materials and solvents linked to Middle East tensions
Commodity pricing volatility in the Ibuprofen business
👀 கவனிக்க வேண்டியவை
Track the outcome of the strategic review regarding the Ibuprofen business expected within the next 12 weeks, and observe margin sustainability amid raw material inflationary pressures.
Solara Active Pharma Reports Q2 FY27 Consolidated PAT of ₹28.46 Cr, Revenue Up 33% YoY to ₹417.34 Cr
Solara Active Pharma Sciences reported a strong turnaround for Q2 ended September 30, 2026, with consolidated revenue from operations rising 33.1% YoY to ₹417.34 Cr compared to ₹313.54 Cr in Q2 FY26. Consolidated net profit reached ₹28.46 Cr versus a net loss of ₹10.10 Cr in the year-ago period, even after absorbing an exceptional loss of ₹4.50 Cr related to the sale of CWIP at its mothballed Vizag plant. For H1 FY27, revenue reached ₹798.94 Cr with a consolidated PAT of ₹44.77 Cr, reflecting continued operational recovery and reduced finance costs (down to ₹17.78 Cr in Q2 from ₹20.83 Cr YoY). Additionally, the company has collected ₹446.62 Cr out of its ₹449.95 Cr rights issue as of September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுApproved unaudited Q2 and H1 FY27 results, showing strong revenue and margin turnaround to net profitability.
ஏன் இது முக்கியம்Demonstrates operational turnaround above the management's target quarterly run-rate of ₹350 Cr+, while balance sheet de-leveraging from rights issue proceeds aids lower interest costs.
Consolidated Q2 Revenue: ₹417.34 கோடிConsolidated Q2 PAT: ₹28.46 கோடிExceptional loss on CWIP sale: ₹4.50 கோடிQ2 வருவாய் vs TTM வருவாய்: ~29.2%Cumulative Rights Issue collected: ₹446.62 கோடி
📅 குறுகிய காலம்Positive sentiment is expected due to sequential and YoY earnings turnaround, exceeding the company's ₹350 Cr quarterly revenue run-rate target.
📈 நீண்ட காலம்Signals stabilization of API operations and potential value unlock from the planned separation of the CRAMS/Polymers business.
⚠ அபாய எச்சரிக்கைகள்
Accumulated standalone losses stand at ₹272.53 Cr as of September 30, 2026
Vizag plant remains mothballed with ongoing asset write-downs/CWIP sales
Commodity/pricing pressure from Chinese API competitors
👀 கவனிக்க வேண்டியவை
Track the sustainability of operating margins in subsequent quarters and observe progress regarding the proposed demerger of the CRAMS and Polymers business via Synthix Global Pharma Solutions.
Solara Shareholders Approve Rs 480 Cr Related Party Transactions with Strides Pharma
Solara Active Pharma Sciences announced the voting results of its 9th Annual General Meeting held on September 18, 2026. All five resolutions were passed with requisite majorities, including the adoption of FY26 financial statements and the reappointment of director Mr. Arun Kumar Pillai. Notably, shareholders approved material related party transactions with Strides Pharma Science Limited for up to Rs 480 crore, which represents approximately 33.5% of Solara's TTM revenue of Rs 1,431 crore. In this resolution, interested promoter entities abstained, and 99.87% of the 78.04 lakh polled public votes were cast in favor.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders officially passed all 9th AGM resolutions, including setting an operational transaction ceiling of Rs 480 crore with Strides Pharma Science Limited.
ஏன் இது முக்கியம்Enables continued commercial supply and service agreements with promoter-linked entity Strides Pharma, representing over a third of Solara's annual revenue base.
Strides RPT limit: Rs 480 croreRPT limit vs TTM revenue: ~33.5%Total shareholders on record date: 71,549RPT approval in-favor vote %: 99.8684%
📅 குறுகிய காலம்Routine administrative closure of the AGM; minimal immediate impact on share price trading.
📈 நீண்ட காலம்Secures the contractual runway for operational collaboration with Strides Pharma, maintaining regular API revenue channels.
⚠ அபாய எச்சரிக்கைகள்
High related-party operational exposure (up to Rs 480 crore transaction cap).
👀 கவனிக்க வேண்டியவை
Track the execution and quarterly disclosures of supply arrangements with Strides Pharma Science to monitor business volume realization relative to the Rs 480 crore ceiling.
Solara Active Pharma: ₹161.92 Cr Tax Demand Dropped to Nil via Rectification Order
Solara Active Pharma Sciences has received a Rectification Order under Section 154 of the Income Tax Act from the IT Department for Assessment Year 2019-20. The order rectifies a previous computation error and completely drops an earlier tax demand of ₹161.92 crore down to Nil. This eliminates a substantial contingent tax overhang equivalent to ~17.5% of the company's market capitalization (₹924 crore) and ~12.9% of its net worth (₹1,256 crore). There are no adverse penalties, non-compliances, or financial impacts remaining from this demand.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Income Tax Department has rectified an erroneous computation, reducing a ₹161.92 crore tax demand for AY 2019-20 to Nil.
ஏன் இது முக்கியம்Eliminates a major potential cash outflow/liability overhang representing ~17.5% of Solara's market capitalization without any financial penalty or liability.
Dropped tax demand: Rs. 161.92 CroresDemand vs Market Cap: ~17.5%Demand vs Net Worth: ~12.9%Applicable Assessment Year: Assessment Year 2019-20
📅 குறுகிய காலம்Positive sentiment driver as a significant disputed tax liability is fully cleared with zero cash outflow.
📈 நீண்ட காலம்Clears balance sheet contingent risk; operational focus remains on API business recovery and utilization of facilities like Vizag.
👀 கவனிக்க வேண்டியவை
Monitor subsequent quarterly filings for confirmation that contingent liability disclosures reflect the cancellation of this ₹161.92 crore tax dispute.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Solara Q1 FY27: PAT up 55% to ₹16.3 Cr; Net Debt reduced by 22% to ₹479 Cr
Solara reported its highest EBITDA and PAT in 18 quarters for Q1 FY27, with total revenue growing 20% YoY to ₹384 Cr. The turnaround is driven by the base business (non-Ibuprofen), which grew 24% YoY to ₹307 Cr with gross margins exceeding 52%. A critical development is the ₹135 Cr reduction in net debt, bringing it down to ₹479 Cr (1.9x annualized EBITDA), largely funded by ₹100 Cr from a rights issue. However, the Ibuprofen segment remains a drag with a negative 12% EBITDA margin due to pricing and supply chain pressures.
உச்சம் நம்பிக்கை
என்ன மாறியதுSolara has achieved its most profitable quarter in 4.5 years and significantly deleveraged its balance sheet using rights issue proceeds and operational cash flow.
ஏன் இது முக்கியம்The reduction in net debt to 1.9x EBITDA and the strong performance of the high-margin base business indicate a successful initial phase of the company's turnaround strategy.
Q1 FY27 Revenue: ₹384 கோடிQ1 FY27 PAT: ₹16.3 கோடிNet Debt: ₹479 கோடிDebt Reduction vs TTM Net Worth: ~10.7%Base Business Gross Margin: 52%Net Debt/EBITDA (Annualized): 1.9x
📅 குறுகிய காலம்The stock may react positively to the significant debt reduction and the highest quarterly profit in several years.
📈 நீண்ட காலம்The long-term outlook depends on the successful scaling of the CRAMS business and resolving the profitability issues in the commodity Ibuprofen segment.
⚠ அபாய எச்சரிக்கைகள்
Negative margins in Ibuprofen segment
Raw material price volatility due to West Asia crisis
Limited working capital
👀 கவனிக்க வேண்டியவை
Watch for the strategic decision on the Ibuprofen business expected by the end of H1 FY27 and the company's ability to sustain 10% growth in the base business amidst raw material price volatility.
₹16.3 Cr PAT; Solara Reports Highest Quarterly Profit in 18 Quarters for Q1 FY27
Solara reported a strong Q1 FY27 with overall revenue growing 20% YoY to ₹384.3 Cr and PAT reaching ₹16.3 Cr, the highest in 18 quarters. The performance was driven by the Base Business (ex-Ibuprofen), which grew 24% YoY, while the Ibuprofen segment continued to drag with an EBITDA loss of ₹8.7 Cr. A significant debt reduction of ₹134.6 Cr was achieved during the quarter, primarily through a rights issue and internal accruals. Management is currently evaluating strategic options for the loss-making Ibuprofen business, with a decision expected by Q2 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has achieved a multi-year high in profitability and significantly deleveraged its balance sheet using rights issue proceeds and operational cash flows.
ஏன் இது முக்கியம்This marks a potential turnaround for Solara, addressing two major investor concerns: high debt levels and the margin-dilutive nature of the commodity Ibuprofen business.
Q1 FY27 Revenue: ₹384.3 கோடிQ1 FY27 PAT: ₹16.3 கோடிDebt Reduction in Q1: ₹134.6 கோடிNet Debt to EBITDA: 1.9xQ1 வருவாய் vs TTM வருவாய்: ~28%
📅 குறுகிய காலம்The stock is likely to react positively to the 'highest profit in 18 quarters' headline and the visible reduction in debt.
📈 நீண்ட காலம்Structural improvement depends on the successful resolution of the Ibuprofen business and the scaling of the CRAMS and non-Ibuprofen API portfolio.
⚠ அபாய எச்சரிக்கைகள்
Continued EBITDA losses in the Ibuprofen segment
Input cost pressures due to geopolitical developments in West Asia
High dependency on regulated market approvals (75%+ of revenue)
👀 கவனிக்க வேண்டியவை
Watch for the management's strategic decision regarding the Ibuprofen business by the end of Q2 FY27, as a potential carve-out or sale could significantly re-rate overall margins.
Solara Active Pharma Sciences has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently attempting to pivot from a stable phase to a growth phase, specifically targeting consistent quarterly revenues of ₹350 Cr+. While the specific Q1 figures were not detailed in the cover letter, the company entered this period following a profitable March 2026 quarter (₹9.73 Cr PAT) after two consecutive loss-making quarters. Investors should focus on whether the operating profit margin (TTM 13.6%) is recovering toward the FY25 level of 16.1%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized and released its financial performance data for the first quarter of the 2026-27 fiscal year.
ஏன் இது முக்கியம்For a company with a TTM net loss of ₹7 Cr and a debt-to-equity ratio of 0.51, consistent quarterly profitability is essential to support its valuation and debt servicing capabilities.
📅 குறுகிய காலம்The stock price may react based on whether the Q1 revenue and margins met the company's internal growth-phase targets of ₹350 Cr+ per quarter.
📈 நீண்ட காலம்Structural recovery depends on the successful expansion of the CRAMS business and managing price competition from Chinese suppliers to maintain a 51% gross margin profile.
⚠ அபாய எச்சரிக்கைகள்
Sensitivity to Chinese price competition
High inventory levels (estimated >120 days)
Regulatory risks (US FDA Import Alerts/Warning Letters)
👀 கவனிக்க வேண்டியவை
Review the detailed quarterly P&L to check if revenue exceeded the ₹350 Cr target and monitor the status of the 'mothballed' Vizag facility, which requires CRAMS partnerships to resume operations.
CRISIL Upgrades Solara Active Pharma's Credit Rating for Rs 791.2 Cr Bank Facilities
CRISIL Ratings has upgraded Solara Active Pharma Sciences Limited's long-term credit rating to 'CRISIL BBB+/Stable' from 'CRISIL BBB/Stable'. Simultaneously, the short-term rating has been upgraded to 'CRISIL A2' from 'CRISIL A3+'. This rating action covers total bank loan facilities amounting to Rs 791.2 crore. The upgrade reflects an improvement in the company's credit profile and financial stability as assessed by the rating agency.
முக்கிய அம்சங்கள்
Long-term rating upgraded to CRISIL BBB+/Stable from CRISIL BBB/Stable.Short-term rating upgraded to CRISIL A2 from CRISIL A3+.Total bank loan facilities covered by the rating amount to Rs 791.2 crore.Major credit facilities include Rs 170 crore from HDFC Bank and Rs 146.5 crore from IDFC FIRST Bank.The rating remains valid until March 31, 2027, under continuous surveillance.
👀 கவனிக்க வேண்டியவை
The credit upgrade is a positive indicator of improving financial health and may lead to reduced interest costs for the company. Investors should consider this a sign of reduced default risk and strengthening fundamentals.
Solara reported a strong Q4 FY26 with revenue growing 12% Q-o-Q to ₹392 crores and EBITDA jumping 65% to ₹61 crores, driven by a high-margin base business. While the base business operates at a robust 26% EBITDA margin, the Ibuprofen segment remains a drag with negative EBITDA, leading the board to appoint bankers for a strategic review expected to conclude in H1 FY27. The company successfully reduced debt by ₹158 crores (21%) during FY26 and expects further reduction to ₹503 crores following the second call of its rights issue. Management highlighted that capacity utilization stands at 70%, providing room for growth without significant immediate capex.
முக்கிய அம்சங்கள்
Revenue grew 12% Q-o-Q to ₹392 crores, marking the highest performance in the last 8 quarters.EBITDA increased 65% Q-o-Q to ₹61 crores with overall margins expanding to 16%.The base business (excluding Ibuprofen) demonstrated superior profitability with 26% EBITDA margins and 54% gross margins.Net debt was reduced by ₹158 crores in FY26, a 21% decrease, with a target to reach ₹503 crores by May 2026.Bankers have been appointed to evaluate strategic options for the loss-making Ibuprofen business, with a conclusion expected in H1 FY27.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the Ibuprofen strategic review in H1 FY27 as a potential re-rating catalyst. The strong performance of the base business and significant debt reduction are positive indicators of a successful operational turnaround.
Solara Reports Zero Deviation in ₹309.79 Cr Rights Issue Fund Utilization
Solara Active Pharma Sciences has confirmed zero deviation in the utilization of proceeds from its Rights Issue for the quarter ended March 31, 2026. The company has raised a total of ₹309.79 crores to date, which includes ₹155.31 crores collected from the first call money. The majority of the funds have been deployed toward debt repayment (₹233.61 crores) and general corporate purposes (₹74.97 crores). As of the reporting date, only ₹1.20 crores remain unutilized in the monitoring agency account.
முக்கிய அம்சங்கள்
Total funds raised via Rights Issue as of March 31, 2026, reached ₹309.79 crores.₹233.61 crores utilized for repayment or pre-payment of outstanding borrowings.₹74.97 crores utilized for General Corporate Purposes (GCP) out of an allocated ₹112.24 crores.First Call money raised amounted to ₹155.31 crores, with ₹154.10 crores already deployed.Audit Committee confirmed no deviations or variations from the objects stated in the Letter of Offer.
👀 கவனிக்க வேண்டியவை
Investors should view the disciplined utilization of funds for debt reduction as a positive sign for the company's balance sheet health. No immediate action is required as the company is adhering to its disclosed capital allocation strategy.
Solara Active Pharma Collects Rs 129.94 Cr via Final Call on Rights Issue Shares
Solara Active Pharma Sciences has successfully received Rs 129.94 crore as the second and final call money for its rights issue. This payment pertains to 1,15,50,478 shares, which have now been converted from partly paid-up to fully paid-up equity shares. The call money consisted of Rs 3.00 towards face value and Rs 109.50 towards securities premium per share. The company is now proceeding with listing and trading approvals for these converted shares, strengthening its equity base and completing the capital raising cycle.
முக்கிய அம்சங்கள்
Received total call money of Rs 129,94,28,775 for 1,15,50,478 rights equity sharesFinal call amount was Rs 112.50 per share, including a securities premium of Rs 109.50Converted 1.15 crore shares from Rs 7 paid-up to Rs 10 fully paid-up equity sharesTotal fully paid-up equity shares now stand at 4,77,25,485Company to seek listing and trading approvals for the newly converted fully paid-up shares
👀 கவனிக்க வேண்டியவை
Investors should monitor the listing of these new fully paid-up shares which will increase the tradeable float. The successful completion of the rights issue fundraise provides the company with necessary capital for its strategic objectives.
Solara Q4 FY26 Revenue Jumps 40% YoY to ₹3,919mn; Base Business EBITDA Margin Hits 26%
Solara reported a strong Q4 FY26 with revenue growing 40% YoY to ₹3,919 million, marking its highest performance in eight quarters. The core 'Base Business' showed significant strength with a 26% EBITDA margin, while the commodity Ibuprofen segment remained a drag with a negative 21% EBITDA margin. Consequently, the company has appointed bankers to explore strategic options for the Ibuprofen business to unlock value. Net debt is on a downward trajectory, expected to reach approximately ₹5,030 million by May 2026 following rights issue proceeds.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 40% YoY to ₹3,919 million, with PAT turning positive at ₹96 million.Base business (excluding Ibuprofen) delivered robust margins with 54% Gross Margin and 26% EBITDA Margin.Ibuprofen business remains a drag with a negative EBITDA of ₹179 million and a negative 21.1% margin in Q4.Net debt reduced from ₹7,719 million in Mar'25 to ₹6,141 million in Mar'26, with a target of ₹5,030 million by May'26.Board has initiated a strategic review of the Ibuprofen business, appointing bankers to evaluate divestment or other options.
👀 கவனிக்க வேண்டியவை
Investors should monitor the strategic review of the Ibuprofen business as a potential exit from this loss-making segment could significantly re-rate the stock. The strong 26% EBITDA margin in the base business indicates a healthy underlying API portfolio.
Solara Active Pharma Reports FY26 Results; Auditors Issue Unmodified Opinion on Net Loss
Solara Active Pharma Sciences approved its audited financial results for the fiscal year ended March 31, 2026, in a board meeting held on May 15, 2026. The company reported a consolidated net loss for the year, although the statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the financial statements. The group's structure evolved during the year with the addition of Synthix Global Pharma Solutions Limited as a wholly-owned subsidiary effective April 29, 2025. Investors should note that while the reporting is transparent, the company remains in a loss-making position on a consolidated basis.
முக்கிய அம்சங்கள்
Board approved audited consolidated and standalone financial results for the full year ended March 31, 2026.Statutory auditors issued an unmodified opinion, confirming the fairness of the reported consolidated net loss.Incorporation of Synthix Global Pharma Solutions Limited as a new wholly-owned subsidiary during the fiscal year.The consolidated results include the performance of four entities: the Parent, Shasun USA Inc., Chemsynth Laboratories, and Synthix Global.The Board meeting was conducted efficiently, commencing at 12:00 PM and concluding at 12:50 PM.
👀 கவனிக்க வேண்டியவை
Investors should scrutinize the full financial statements to identify the specific drivers behind the consolidated net loss and assess the company's path to profitability. Monitor the contribution of the newly formed subsidiary, Synthix Global, in upcoming quarterly reports.
Solara Receives US FDA EIR for Puducherry Facility with VAI Classification
Solara Active Pharma Sciences has successfully closed a US FDA inspection at its Puducherry Ibuprofen manufacturing facility. The unannounced inspection, conducted between February 2 and February 6, 2026, initially resulted in four procedural Form 483 observations. Following the company's timely response, the US FDA issued an Establishment Inspection Report (EIR) on April 24, 2026, classifying the facility as Voluntary Action Indicated (VAI). This closure confirms continued cGMP compliance and secures the regulatory standing of a key site catering to international markets.
முக்கிய அம்சங்கள்
Successful closure of US FDA inspection at the Puducherry Ibuprofen manufacturing siteReceived Establishment Inspection Report (EIR) with 'Voluntary Action Indicated' (VAI) status on April 24, 2026Inspection conducted from Feb 2 to Feb 6, 2026, resulted in 4 procedural Form 483 observationsThe Puducherry site is a core facility approved by multiple global agencies including US FDA, EDQM, and MHRA
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant positive development that removes regulatory overhang on a key manufacturing asset. The successful EIR receipt validates the company's quality systems and ensures uninterrupted supply to the US market.
Solara Pharma Announces Final Call of ₹112.50 per Rights Share; Record Date April 2, 2026
Solara Active Pharma Sciences has approved the second and final call for its partly paid-up rights shares. Shareholders holding these shares as of the record date, April 2, 2026, will be required to pay ₹112.50 per share. This payment consists of ₹3.00 towards face value and ₹109.50 towards securities premium. This procedural step completes the capital raising process initiated via the rights issue in May 2024.
முக்கிய அம்சங்கள்
Second and final call amount set at ₹112.50 per equity share.Record date for identifying eligible partly-paid shareholders is April 02, 2026.Call price breakdown: ₹3.00 face value and ₹109.50 securities premium per share.Relates to the rights issue originally offered via the Letter of Offer dated May 09, 2024.
👀 கவனிக்க வேண்டியவை
Investors holding partly paid shares (SOLARAPP1) must pay the final call amount to convert them into fully paid shares. Failure to pay by the specified deadline will lead to the forfeiture of the shares and the initial investment.
Solara Active Pharma Receives ₹161.92 Crore Income Tax Demand Notice
Solara Active Pharma Sciences has received a significant tax demand notice of ₹161.92 Crores from the Income Tax Department for the Assessment Year 2019-20. The demand stems from the disallowance of certain expenses claimed by the company in its tax filings. The company has stated its intention to file an appeal against this order before the relevant Appellate Authority. Management believes the case has merit and does not currently expect a material financial impact, though the amount is substantial.
முக்கிய அம்சங்கள்
Received a Tax Demand Notice of ₹161.92 Crores under Section 156 of the Income Tax Act, 1961.The demand pertains to Assessment Year 2019-20 following an audit of claimed expenses.The order was passed by the Deputy Commissioner of Income Tax, Central Circle-3, Thane.Company plans to contest the demand by filing an appeal with the Appellate Authority.Management maintains that there will be no material financial impact due to the merits of their case.
👀 கவனிக்க வேண்டியவை
Investors should monitor the legal proceedings as the demand amount is significant relative to the company's financials. While the company is contesting, any unfavorable final ruling could impact cash flows.
Solara Shareholders Approve Mohanraj Sanjeevi as Whole-time Director with 99.97% Majority
Solara Active Pharma Sciences Limited has announced the successful passage of a special resolution to appoint Mr. Mohanraj Sanjeevi as a Whole-time Director for a three-year term. The resolution received overwhelming support, with 99.97% of the 26.04 million votes cast in favor. Mr. Sanjeevi's remuneration is set at a fixed Rs. 85 lakh per annum plus a variable component of Rs. 15 lakh. This appointment, effective from January 1, 2026, ensures leadership stability for the company's executive operations.
முக்கிய அம்சங்கள்
Special resolution for appointment passed with 99.97% majority (26,032,102 votes in favor).Mr. Mohanraj Sanjeevi appointed for a 3-year term effective from January 1, 2026, to December 31, 2028.Total annual remuneration package includes Rs. 85 lakh fixed and Rs. 15 lakh variable pay.Promoter and institutional investor groups both voted 100% in favor of the resolution.Overall voter turnout represented 58.64% of the total outstanding shares of the company.
👀 கவனிக்க வேண்டியவை
The high level of shareholder support indicates strong confidence in the executive leadership. Investors should view this as a routine governance step providing management continuity.
Solara Q3 FY26: Growth API Margins at 25% Amid Strategic Review of Ibuprofen Business
Solara reported Q3 FY26 revenue of INR 346 crores, up 10% Q-o-Q, though consolidated gross margins fell to 47% due to headwinds in the base ibuprofen business. The non-ibuprofen 'growth' segment is performing exceptionally well with 56% gross margins and 25% EBITDA margins, significantly outperforming the commodity business. Management has initiated a strategic review of the ibuprofen division, which is currently utilizing only 3,000 tons of its 6,000-ton Pondicherry capacity. The company successfully reduced debt by INR 146 crores (19%) and targets a sub-INR 500 crore debt level by May 2026.
முக்கிய அம்சங்கள்
Revenue grew 10% Q-o-Q to INR 346 crores; EBITDA stood at INR 37 crores with an 11% margin.Non-ibuprofen growth business achieved high-tier margins of 56% (gross) and 25% (EBITDA).Ibuprofen capacity utilization remains low at 50% for the Pondicherry plant (3,000 of 6,000 tons).Debt was reduced by INR 146 crores (19%) during the quarter, aided by rights issue proceeds.A one-time exceptional cost of INR 6.7 crores was incurred due to the new labor wage code implementation.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the Q4 announcement regarding the strategic review of the ibuprofen business, as a potential restructuring or hive-off could unlock significant value from the high-margin growth API segment.
Solara Reports Zero Deviation in ₹308.85 Cr Rights Issue Fund Utilization
Solara Active Pharma Sciences has confirmed that there is no deviation or variation in the utilization of ₹308.85 crores raised through its Rights Issue as of December 31, 2025. The company has primarily used the proceeds for debt reduction, with ₹233.61 crores allocated to the repayment or pre-payment of borrowings. Additionally, ₹74.97 crores have been utilized for general corporate purposes out of a total planned allocation of ₹112.24 crores. The Audit Committee and monitoring agency CRISIL have reviewed and approved these statements without any adverse comments.
முக்கிய அம்சங்கள்
Total funds raised through the Rights Issue amounted to ₹308.85 crores as of December 31, 2025.A significant portion of ₹233.61 crores was utilized for the repayment or pre-payment of outstanding borrowings.₹74.97 crores were deployed for General Corporate Purposes (GCP), adhering to the 25% cap of gross proceeds.The company reported zero deviation from the objects mentioned in the Letter of Offer dated May 09, 2024.A minor balance of ₹0.26 crores remains in the escrow account to be utilized in upcoming quarters.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's disciplined use of capital for debt reduction, which should improve the balance sheet. Monitor upcoming earnings reports to see the positive impact of reduced interest costs on the bottom line.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
